The Claim
Semaglutide reduces neutrophil adhesion to aortic endothelial cells under high glucose conditions in vitro through downregulation of CD11b expression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Semaglutide decreases the sticking of neutrophils to blood vessel lining cells when glucose levels are high, by reducing the amount of CD11b protein on the neutrophils.
See the scientific wording
Semaglutide reduces neutrophil adhesion to aortic endothelial cells under high glucose conditions in vitro, an effect mediated by downregulation of CD11b, suggesting a direct anti-adhesive mechanism that may limit early atherosclerosis.
Semaglutide binds to receptors on fat cells and white blood cells, causing fat cells to release less of a sticky protein that activates white blood cells. This makes the white blood cells express less of a surface protein that grabs onto artery walls. As a result, fewer white blood cells stick to the artery lining, even when sugar levels are high.
What the research says
1 studyIn lab tests, the diabetes drug semaglutide made white blood cells stick less to artery walls, especially when sugar levels were high, by turning down a sticky protein called CD11b — which could help prevent early artery damage.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.